Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that approximately half of newly diagnosed patients with asthma do not receive any form of pharmacological treatment within 360 days of their diagnosis. The new report entitled Treatment Algorithms in Asthma finds that drug treatment rate is low because patients face significant out-of-pocket expenses for asthma treatment. In addition, physicians note that drug treatment rates might be low because the symptoms may improve upon treatment in an urgent care setting following which patients may not present to a physician again.

The report also finds that primary care physicians vary from recommended guidelines to prescribe GlaxoSmithKline's Advair as first-line therapy in cases where it is recommended to start with an inhaled corticosteroid.

"Both our data and thought leaders suggest primary care physicians are prescribing Advair in earlier lines of treatment than recommended by treatment guidelines," said Madhuri Borde, Ph.D., analyst. "PCPs like Advair for its efficacy, fast symptom relief, and short term side-effect/safety profile, and are also influenced by their familiarity with the agent."

Treatment Algorithms for Asthma allows pharmaceutical organizations to quantify lines of therapy through primary research and patient-level data. Users can:

  * Understand current treatment patterns and anticipate future market     dynamics   * Drive product growth through accurate knowledge of a product's     positioning among the lines of therapy and why physicians use it at that     point   * Target specific competitors that are preceding or following a product     and benefit from actionable analysis of the path to treatment and     physicians' decision parameters   * Develop more sophisticated market-forecasting patient-flow models based     on the unique, accurate information regarding the percentage of patients     receiving a product at specific stages in the line of therapy    About Treatment Algorithm Insight Series 

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

  * Summary of U.S. medical practice based on interviews with leading     experts in the field   * Qualitative diagnosis/referral/treatment algorithm for the United States   * Drug usage by lines of therapy (1st, 2nd, 3rd line)   * Discussion of key freeform combinations by lines of therapy   * Product share (class and specific compound level) within each line of     therapy (1st, 2nd, 3rd line)   * Progression of therapy from key 1st line products   * Pathway to key therapies from previous therapies   * Qualitative analysis of 2-year forecast incorporating upcoming launches,     changes in reimbursement, etc.    About Decision Resources 

Decision Resources, Inc., ( is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

  All company, brand, or product names contained in this document may be      trademarks or registered trademarks of their respective holders.    For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,

Abbott/Eisai's Humira and UCB's Cimzia Will Drive Sales of TNF-Alpha Inhibitors to $1.3 Billion in the Market to Treat Crohn's Disease

View Now